Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs TJX Companies Inc (TJX) Price & Performance

CVS Health CorpTrade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs TJX Companies Inc — how do they compare? CVS Health Corp trades at $93.5 (market cap $119.58B), while TJX Companies Inc trades at $154.17 (market cap $172.05B). The key difference: TJX Companies Inc is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.

CVSTJX
Market Cap
$119.58B$172.05B
Sector
HealthConsumer Cyclical
52-Week High
$110.60$168.41
52-Week Low
$65.51$132.62
Enterprise Value
$181.93B$180.65B
Dividend Yield
2.84%1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.

The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.

TJX Companies Inc

TJX trades at $158.80, down 1.59% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $158 and resistance at $160, while analyst consensus remains overwhelmingly positive with 88% buy ratings and a $181.80 price target. Recent financial performance demonstrates solid revenue growth from $48.5B in 2022 to $56.4B in 2025, with net income margins expanding to 8.63%.

TJX presents a compelling investment case with strong operational execution and market share gains in discount retail. The primary upside catalyst is continued earnings outperformance and expansion into new markets, while risks include consumer spending sensitivity and competitive pressures. With projected 2026 revenue of $61.6B and net income of $5.8B, the company's growth trajectory supports the bullish analyst sentiment despite premium valuation multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX